A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Inclusion Criteria:

• Participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures being performed.

• Participants is ≥18 years of age at the time of signing the ICF.

• Participants with histopathologically or immunohistochemically confirmed NHLaccording to 2016 World Health Organization (WHO) haematolymphoid tumors criteriaclassification (CLL/SLL diagnosis according to 2018 IWCLL) who have failed standardof care therapy or lack an effective treatment regimen.

• Participants in Phase Ib screening period with measurable lesion, but no measurablenodal lesion limit for participants in Phase Ia.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.

• Life expectancy > 3 months.

• Good performance of major organs, including hematology, liver and kidney function,and coagulation. etc.

• Participants are willing and able to adhere to the study visit schedule and otherprotocol requirements.

Exclusion Criteria:

• Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy,immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives,whichever is shorter, prior to the first dose of GLB-002; or chimeric antigenreceptor T cell therapy (CAR-T) within 3 months prior to the first dose of GLB-002.

• Currently enrolled in any other investigational drug study or participation withinthe last 28 days or 5 half-lives, whichever is shorter, prior to the first dose ofGLB-002 (exception of participants who participated in only one investigational drugstudy with overall survival follow-up).

• Participants with unresolved clinically significant toxicities of > Grade 1 AE ornot be recovered to baseline value from prior anticancer therapies with exception ofalopecia or hyperpigmentation of the skin.

• Participants who are scheduled to receive other anticancer therapies or otherinvestigational drugs during the study period.

• Participants with active acute or chronic graft versus host disease (GVHD) requiringsystemic immunosuppressive therapy, or participants requiring treatment withsystemic corticosteroids (>10 mg/day prednisone or equivalent) or otherimmunosuppressive drugs within the last 7 days prior to the first dose of GLB-002 orduring the study period.

• Receipt of Autologous Stem Cell Transplantation (ASCT) within the last 3 months, orallogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6months prior to the first dose of GLB-002.

• Participants with known active leukemic involvement in central nervous system (CNS).

• Participants with peripheral neuropathy ≥ Grade 2 (Graded according to CTCAE version 5.0).

• History of, or current active cancer other malignancy for the past 5 years, with theexception of curatively resected cancer in situ, including cervical carcinoma insitu, basal cell carcinoma of the skin, or prostate cancer in situ, etc

• QT interval interval >470 milliseconds (ms) using electrocardiographic (ECG) atScreening.

• Participants has impaired cardiac function or clinically significant cardiac diseaseat current or within last 6 months.

• Participants with known active infection of hepatitis B virus (HBV) or hepatitis Cvirus C (HCV).

• Participants with known human immunodeficiency virus (HIV) infection.

• Participants with known life-threatening or clinical significant uncontrolled activesystemic infections unrelated to malignant hematologic diseases

• Participants with a condition that may affects the absorption, distribution,metabolism and excretion of GLB-002.

• Medications or supplements that are known to be strong and moderate inhibitors orinducers of cytochrome P-450 isozyme (CYP)3A4/5 and/or P-glycoprotein (P-gp) within 7 days or 5 half-lives prior to the first dose of GLB-002, whichever is shorter.

• Participants who have undergone major surgery within 28 days prior to the first doseof the GLB-002.

• Pregnant or lactating women.

• Participants who have cognitive impairment due to any psychiatric or neurologicalcondition, including epilepsy and dementia, may limit their understanding,performance, and study compliance with the ICF.

• Participants,in the opinion of the Investigator, who are unsuitable to participatein the study.